Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials

摘要: 1508 Background: Egf receptor variant III (vIII) is an aberrant tyrosine kinase that lacks a substantial portion of full length receptor's extracellular domain, and has been suggested as being exclusively expressed in human glioblastoma. Little known, however, with regard to the prognostic significance vIII expression Methods: To assess associations between malignant glioma classification, well asses its significance, tumor tissues were collected from patients enrolled 10 prospective clinical trials, these examined for by immunohistochemistry. Of 168 evaluable specimens, 63 classified grade malignancy (56 anaplastic astrocytomas 7 oligoastrocytomas), 105 IV tumors (glioblastoma multiforme), based on WHO criteria. All received radiation therapy nitrosourea-based adjuvant chemotherapy without any difference outcome related treatment...